Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor. In this report, we show that modulation of s...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Grohar, Patrick J, Griffin, Laurie B, Yeung, Choh, Chen, Qing-Rong, Pommier, Yves, Khanna, Chand, Khan, Javed, Helman, Lee J
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press Inc. 2011
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033593/
https://ncbi.nlm.nih.gov/pubmed/21403840
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky